These questions and answers (Q&As) provide an overview of the European Medicines Agency's (EMA) advice on issues that are typically addressed in discussions or meetings with marketing authorisation holders in the application phase.
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.